Tag: failures

HOUSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Fervo Energy Company (“Fervo” or the “Company”) (NASDAQ: FRVO), a leading technology-enabled independent power producer of Enhanced Geothermal Systems (EGS), today reported financial and operational results for the first quarter ended March 31, 2026.

New platform will integrate real-time field data, physics-based modeling, and AI to advance critical geothermal infrastructure and maximize power generation

NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- National Healthcare Properties, Inc. (Nasdaq: NHP / NHPAP / NHPBP) (the “Company”), a self-managed real estate investment trust focused on acquiring, owning and investing in a diversified portfolio of healthcare real estate, with an emphasis on providing senior housing to serve a growing elderly population in the United States, today announced the preliminary results of its concurrent but separate offers to purchase up to a maximum aggregate purchase price in cash of $100 million of (i) its 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share (the “Series A Shares”), and (ii) its 7.125% Series B Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share (the “Series B Shares,” and together with the Series A Shares, the “Shares”), in each case for a purchase price of $22.50 per share in cash (collectively, the “Offers”), each less any applicable withholding taxes and without interest. The Offers each expired at 5:00 p.m., New York City time, on June 16, 2026 (the “Expiration Date”).

MILWAUKEE, June 16, 2026 (GLOBE NEWSWIRE) -- Fiserv, Inc. (NASDAQ: FISV) (the “Company”), a leading global provider of payments and financial services technology solutions, today announced the commencement of tender offers to purchase for cash any and all of the senior notes issued by the Company listed in the table below (collectively, the “Notes”). The tender offers (the “Offers”) are being made pursuant to the Offer to Purchase, dated June 16, 2026 (the “Offer to Purchase”).

Quickwork's new on-premises, virtual private cloud (VPC), and air-gapped deployment capabilities enable enterprises to run integration, automation, and AI workflows entirely within their own controlled infrastructure environments.

BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The results are being presented today in a late-breaking session at the European Hematology Association (EHA) 2026 Congress (Abstract #LB5006).